Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results

被引:25
作者
Gibson, CM
Ryan, KA
Kelley, M
Rizzo, MJ
Mesley, R
Murphy, S
Swanson, J
Marble, SJ
Dodge, JT
Giugliano, RP
Cannon, CP
Antman, EM
机构
[1] Allegheny Gen Hosp, Dept Med, Div Cardiovasc, Pittsburgh, PA 15212 USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
D O I
10.1016/S0002-8703(99)70380-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The Thrombolysis in Myocardial Infarction (TIMI) Study Group originally defined TIMI grade 3 flow (complete perfusion) as antegrade flow into the bed distal to the obstruction that occurs as promptly as antegrade flow into the bed proximal to the obstruction. Recently, several groups have defined TIMI grade 3 flow as opacification of the coronary artery within 3 cardiac cycles. Methods and Results On the basis of heart rate data at the time of the cardiac catheterization and the time for dye to go down the artery (TIMI frame count/30 = seconds), we estimated the number of patients who would meet the 3 cardiac cycle criterion and compared this with the number of patients with TIMI grade 3 flow by using the original definition in 1157 patients from 3 recent TIMI trials (10 A, 10B, and 14). In 74 patients without acute myocardial infarction and normal coronary arteries, the fraction of a cardiac cycle required for dye to traverse the artery was a mean of 0.93 +/- 0.34 cardiac cycles (n = 74) (median 0.80, minimum 0.44, maximum 2.1, none >3.0 cycles). The mean heart rate at 90 minutes after thrombolysis in the TIMI 14 trial was 79.6 +/- 16.8 beats/min (n = 194), and the duration of 3 cardiac cycles was a mean of 2.36 seconds, or a TIMI frame count of 70.8 frames. In all trials, the rate of TIMI grade 3 flow was 57.3% (n = 663/1157) with the original definition and 66.8% (n = 743/1113) with the <3 cardiac cycle definition (P < .001). Conclusions A duration of 3 cardiac cycles for dye to traverse the artery lies approximately 6 SD above that observed in normal coronary arteries. A 3 cardiac cycle definition of TIMI grade 3 flow results in rates of normal perfusion that are approximately 10% higher than if the original definition of TIMI grade 3 flow is applied. Application of this simple correction factor may help place data reported with the 3 cardiac cycle definition of TIMI grade 3 flow in context.
引用
收藏
页码:1179 / 1184
页数:6
相关论文
共 32 条
  • [1] Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial
    Antman, EM
    Giugliano, RP
    McCabe, CH
    Gibson, M
    Adgey, AJJ
    Ghali, M
    Coussement, P
    Anderson, KM
    Scherer, J
    Van de Werf, F
    Braunwald, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 191A - 191A
  • [2] Betriu A, 1997, NEW ENGL J MED, V336, P1621
  • [3] Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (Recombinant plasminogen activator) and front-loaded, accelerated alteplase (Recombinant tissue plasminogen activator) in patients with acute myocardial infarction
    Bode, C
    Smalling, RW
    Berg, G
    Burnett, C
    Lorch, G
    Kalbfleisch, JM
    Chernoff, R
    Christie, LG
    Feldman, RL
    Seals, AA
    Weaver, WD
    [J]. CIRCULATION, 1996, 94 (05) : 891 - 898
  • [4] COMPARISON OF FRONT-LOADED RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, ANISTREPLASE AND COMBINATION THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) 4 TRIAL
    CANNON, CP
    MCCABE, CH
    DIVER, DJ
    HERSON, S
    GREENE, RM
    SHAH, PK
    SEQUEIRA, RF
    LEYA, F
    KIRSHENBAUM, JM
    MAGORIEN, RD
    PALMERI, ST
    DAVIS, V
    GIBSON, CM
    POOLE, WK
    BRAUNWALD, E
    PULEO, P
    ABENDSCHEIN, D
    LOSCALZO, J
    CHAITMAN, BR
    ZARET, BL
    DANGOISSE, V
    FLAKER, GC
    GARRISON, TW
    SCHWEIGER, MJ
    MAHRER, PR
    SHOOK, TL
    ANDERSON, JL
    PALISAITIS, D
    COHN, PF
    LARAMEE, LA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (07) : 1602 - 1610
  • [5] Cannon CP, 1997, CIRCULATION, V95, P351
  • [6] CANNON CP, 1997, CIRCULATION S1, V96, P206
  • [7] RANDOMIZED ANGIOGRAPHIC TRIAL OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR (ALTEPLASE) IN MYOCARDIAL-INFARCTION
    CARNEY, RJ
    MURPHY, GA
    BRANDT, TR
    DALEY, PJ
    PICKERING, E
    WHITE, HJ
    MCDONOUGH, TJ
    VERMILYA, SK
    TEICHMAN, SL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (01) : 17 - 23
  • [8] DDOGE JT, 1998, AM J CARDIOL, V81, P1268
  • [9] IMMEDIATE CORONARY ANGIOPLASTY VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL-INFARCTION - LEFT-VENTRICULAR EJECTION FRACTION, HOSPITAL MORTALITY AND REINFARCTION
    DEBOER, MJ
    HOORNTJE, JCA
    OTTERVANGER, JP
    REIFFERS, S
    SURYAPRANATA, H
    ZIJLSTRA, F
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) : 1004 - 1008
  • [10] Dodge JT, 1998, CATHETER CARDIO DIAG, V44, P34, DOI 10.1002/(SICI)1097-0304(199805)44:1<34::AID-CCD9>3.0.CO